Path to “Alnylam 2020” Presented at R&D Day 2015

Path to “Alnylam 2020” Presented at R&D Day 2015

On December 10, 2015, we hosted our third consecutive R&D Day in New York City. Alnylam management and key opinion leaders discussed our most advanced clinical programs, reviewing all the latest data and providing guidance on development plans for the ATTR amyloidosis programs, fitusiran (ALN-AT3), ALN-CC5, ALN-AS1, and ALN-PCSsc.




.
You may also access specific sections of the presentation below:









SIGN UP FOR PATIENT CONNECT

Receive updates on our investigational therapies and clinical trials.